Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

NCT05714371 · clinicaltrials.gov ↗

COMPLETED

Status

618

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab + nivolumab
DRUG: Pembrolizumab
DRUG: Dabrafenib + trametinib

Sponsor

Novartis Pharmaceuticals